must read, page-4

ATL drugs are certainly not the showcase of this presentation, rather a side show, but we are part of a global push towards commercialisation of this technology with broad applications and interest from accross the biotech spectrum, represented by interest from the largest players.


Cardiovascular clot preventing drugs for thrombotic diseases, the Biogen partnership for SMA, GSK partnership for TTR drugs are the cornerpieces of this presentation.


What is remarkable is the fact that those large companies are involved in many cases during or pior to phase 1 clinical trials already and the business model is explained in detail between those companies and ISIS, allowing upfront payments to allow financing those programs but restructuring the deal for proper license royalty figures once clinical trials are successfully completed.

In that context, it seems more than likely that ANP has lined up its financing for ATL1103 phase 2 trials in a similar fashion to be in the position to be able to renegotiate favourable terms for final contracts after positive phase 2 trials which could be numerous, see Mipomersen's 20 clinical trials.




It does not surprise that our shareprice undergoes currently such rampant manipulation when considering that ISIS locks in partnerships for its programs at phase 1 trial stages. Larger investors can anticipate such developments for ATL1103.
All week buyers were in control and I expect a similar display for next week with new highs.
The fabricated lows at the end of nearly all sessions are a clear giveaway.

T4P's theory of recommendation does fit into this concept.



ANP does claim it wants to finance P2 trials itself but I would suggest that a similar financial arrangement as mentioned above for ISIS is currently negotiated with partners.

The amount of successful trials for ISIS with Mipomersen turning commercial is the perfect basis for a strong performance of ANP in the short and medium term.